Intellia Therapeutics Inc (NASDAQ: NTLA) on Tuesday, plunged -3.86% from the previous trading day, before settling in for the closing price of $9.58. Within the past 52 weeks, NTLA’s price has moved between $9.25 and $34.87.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 4.71% annually for the last half of the decade. The company achieved an average annual earnings per share of 1.99%. With a float of $95.61 million, this company’s outstanding shares have now reached $101.80 million.
In an organization with 526 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 82.41%, operating margin of -1247.99%, and the pretax margin is -1212.19%.
Intellia Therapeutics Inc (NTLA) Insider and Institutional Ownership
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Intellia Therapeutics Inc is 6.13%, while institutional ownership is 90.25%. The most recent insider transaction that took place on Jan 29 ’25, was worth 2,642. In this transaction Director of this company sold 265 shares at a rate of $9.97, taking the stock ownership to the 19,468 shares. Before that another transaction happened on Jan 03 ’25, when Company’s VP, Chief Accounting Officer sold 1,372 for $12.18, making the entire transaction worth $16,711. This insider now owns 45,640 shares in total.
Intellia Therapeutics Inc (NTLA) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.36 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 1.99% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 2.76% during the next five years compared to -22.30% drop over the previous five years of trading.
Intellia Therapeutics Inc (NASDAQ: NTLA) Trading Performance Indicators
Intellia Therapeutics Inc (NTLA) is currently performing well based on its current performance indicators. A quick ratio of 6.73 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 21.77.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -5.45, a number that is poised to hit -1.33 in the next quarter and is forecasted to reach -5.13 in one year’s time.
Technical Analysis of Intellia Therapeutics Inc (NTLA)
Let’s dig in a bit further. During the last 5-days, its volume was 2.29 million. That was inferior than the volume of 2.96 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 19.88%. Additionally, its Average True Range was 0.71.
During the past 100 days, Intellia Therapeutics Inc’s (NTLA) raw stochastic average was set at 0.89%, which indicates a significant decrease from 5.46% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 65.24% in the past 14 days, which was lower than the 74.92% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $11.83, while its 200-day Moving Average is $19.16. However, in the short run, Intellia Therapeutics Inc’s stock first resistance to watch stands at $9.43. Second resistance stands at $9.65. The third major resistance level sits at $9.83. If the price goes on to break the first support level at $9.03, it is likely to go to the next support level at $8.86. The third support level lies at $8.64 if the price breaches the second support level.
Intellia Therapeutics Inc (NASDAQ: NTLA) Key Stats
Market capitalization of the company is 938.03 million based on 101,849K outstanding shares. Right now, sales total 36,280 K and income totals -481,190 K. The company made 9,110 K in profit during its latest quarter, and -135,710 K in sales during its previous quarter.
